Skip to content

Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer

Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03126994
Enrollment
160
Registered
2017-04-25
Start date
2017-04-11
Completion date
2017-05-19
Last updated
2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor

Brief summary

This is a prospective, single-center, non-randomized validation study being conducted under a non-significant risk study design with the primary aim to evaluate PWV, PR, and BW accuracy in a sample of subjects representative of the US general adult population. The primary study objective is to demonstrate equivalency when measuring: Pulse Wave Velocity (PWV) and Pulse Rate (PR) between the PhysioWave Cardiovascular Analyzer (CA) and AtCor Medical SphygmoCor® XCEL PWA & PWV (XCEL), and Body Weight (BW) between the CA and the Detecto Solo Digital Healthcare Scale (Detecto).

Interventions

DEVICEPhysioWave Cardiovascular Analyzer

Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI

DEVICEAtCor XCEL PWA & PWV

Measurement of Pulse Wave Velocity and Pulse Rate

DEVICEDetecto SOLO

Measurement of Body Weight and BMI

Sponsors

PhysioWave, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Prospective validation study to evaluate PWV, PR, and BW accuracy in a sample of subjects representing the US general adult population.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects \>18 years old * Subject signs a written Informed Consent form to participate in the study, prior to any study procedures Subgroup Inclusion Criteria * Subject has been taking ACE Inhibitors or Angiotensin Receptor Blockers for at least 30 days

Exclusion criteria

* Known significant carotid or femoral artery stenosis * Non-palpable (non-detectable) arterial pulse at the sites of measurements * Pacemaker, defibrillator, or other cardiac stimulator * Erratic, accelerated or mechanically controlled irregular heart rhythm, or an arrhythmia * History of cardiac valve disorder or cardiac valve disease * History of venous disease, including venous insufficiency or deep vein thrombosis * History of peripheral artery disease * Requirement for supplemental oxygen * Neuromuscular disorders that cause shaking or tremors (such as Parkinson's disease or Multiple Sclerosis), or other disease or condition affecting balance * Amputation or malformation of any limb or extremity (foot, leg, or arm) which would impede the placement of blood pressure cuffs or standing on the scale with two feet. * Known or suspected pregnancy * Inability to provide informed consent * Mental incompetence or a prisoner status * Current participation in a clinical trial of another investigational drug or device in which the study endpoint has not been met * BMI \> 40 * Subjects \> 400 lbs * Subjects on strong vasoactive drugs, such as those used to control high blood pressure, for \<30 days * Blood loss or blood donation of ˃ 550 mL within 30 days before study procedure

Design outcomes

Primary

MeasureTime frameDescription
Pulse Rate EquivalenceDay 1The second primary study objective is to demonstrate equivalency when measuring: pulse rate (in bpm) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV.
Body Weight EquivalenceDay 1The third primary study objective is to demonstrate equivalency when measuring body weight (in kg) between the PhysioWave Cardiovascular Analyzer and the Detecto Solo.
Primary Objective: PWV EquivalenceDay 1The first primary study objective is to demonstrate equivalency when measuring: pulse wave velocity (PWV) (in m/s) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV.

Secondary

MeasureTime frameDescription
Secondary Objective: Precision Analysis, Pulse RateDay 1 or Day 2Evaluate the precision of pulse rate measurements (in bpm) due to the sources of variation in measurements in the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV. Sources of variation to be assessed include between-replicates, between-device, between-operator, and total (overall).
Secondary Objective: Precision Analysis, BMIDay 1 or Day 2Evaluate the precision of BMI measurements (in kg/m\^2) due to the sources of variation in measurements in the PhysioWave Cardiovascular Analyzer and the Detecto Solo. Sources of variation to be assessed include between-replicates, between-device, between-operator, and total (overall).
Secondary Objective: Precision Analysis, Body WeightDay 1 or Day 2Evaluate the precision of body weight measurements (in kg) due to the sources of variation in measurements in the PhysioWave Cardiovascular Analyzer and the Detecto Solo. Sources of variation to be assessed include between-replicates, between-device, between-operator, and total (overall).
Secondary Objective: BMI EquivalenceDay 1Demonstrate equivalency when measuring Body Mass Index (BMI) (in kg/m\^2) between the PhysioWave Cardiovascular Analyzer and the Detecto Solo
Secondary Objective: Precision Analysis, PWVDay 1 or Day 2Evaluate the precision of PWV measurements (in m/s) due to the sources of variation in measurements in the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV. Sources of variation to be assessed include between-replicates, between-device, between-operator, and total (overall).

Other

MeasureTime frameDescription
Exploratory Analysis: Impact of Strong Vasoactive Drugs on PWV EquivalenceDay 1An exploratory analysis will be conducted to evaluate any effects of strong vasoactive drugs, such as those used to control high blood pressure, on equivalency when measuring: pulse wave velocity (PWV) (in m/s) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV.
Exploratory Analysis: Impact of BMI on PWV EquivalenceDay 1An exploratory analysis will be conducted to evaluate any effect(s) of BMI (in kg/m\^2) on equivalency when measuring: pulse wave velocity (PWV) (in m/s) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA & PWV.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026